<table border="0" cellpadding="0" cellspacing="0" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col width="329pt"></col>
<col width="329pt"></col>
<tbody>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="bold">Inhibitors</content>
<content stylecode="bold"> of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics"> Clinical </content>
<content stylecode="italics">Impact:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets for oral suspension and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets for oral suspension is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above.</paragraph>
<paragraph>After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline,</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "></td>
<td>
<paragraph>the methadone plasma concentration can decrease <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#LINK_7ef8cd10-7304-49b7-aa35-8ebc33fadce9">12.3</linkhtml>)]</content>, resulting in decreased opioid efficacy or withdrawal symptoms in patients physically dependent on methadone.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>If concomitant use is necessary, consider dosage reduction of methadone hydrochloride tablets for oral suspension until stable drug effects are achieved. Monitor patients for respiratory depression and sedation at frequent intervals.</paragraph>
<paragraph>If a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor is discontinued, follow patients for signs of opioid withdrawal and consider increasing the methadone hydrochloride tablets for oral suspension dosage until stable drug effects are achieved.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), protease inhibitors (e.g., ritonavir), fluconazole, fluvoxamine, some selective serotonin reuptake inhibitors (SSRIs) (e.g., sertraline, fluvoxamine)</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="bold">Inducers</content>
<content stylecode="bold"> of CYP3A4, CYP2B6, CYP2C19, or CYP2C9</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>The concomitant use of methadone hydrochloride tablets for oral suspension and CYP3A4, CYP2B6, CYP2C19, or CYP2C9 inducers can decrease the plasma concentration of methadone <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#LINK_7ef8cd10-7304-49b7-aa35-8ebc33fadce9">12.3</linkhtml>)]</content>, resulting in decreased efficacy or onset of withdrawal symptoms in patients physically dependent on methadone. These effects could be more pronounced with concomitant use of drugs that can induce multiple CYP enzymes.</paragraph>
<paragraph>After stopping a CYP3A4, CYP2B6, CYP2C19, or CYP2C9 inducer, as the effects of the inducer decline, the methadone plasma concentration can increase <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#LINK_7ef8cd10-7304-49b7-aa35-8ebc33fadce9">12.3</linkhtml>)]</content>, which could increase or prolong both the therapeutic effects and adverse reactions, and may cause serious respiratory depression, sedation, or death.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>If concomitant use is necessary, consider increasing the methadone hydrochloride tablets for oral suspension dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal. If a CYP3A4, CYP2B6, CYP2C19, or CYP2C9 inducer is discontinued, consider methadone hydrochloride tablets for oral suspension dosage reduction and monitor for signs of respiratory depression and sedation.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Rifampin, carbamazepine, phenytoin, St. Johnâ€™s Wort, Phenobarbital</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="bold">Potentially</content>
<content stylecode="bold"> Arrhythmogenic Agents</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Pharmacodynamic interactions may occur with concomitant use of methadone and potentially arrhythmogenic agents or drugs capable of inducing electrolyte disturbances (hypomagnesemia, hypokalemia).</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Monitor patients closely for cardiac conduction changes.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Drugs known to have potential to prolong QT interval: Class I and III antiarrhythmics, some neuroleptics and tricyclic antidepressants, and calcium channel blockers. Drugs capable of inducing electrolyte disturbances: Diuretics, laxatives, and, in rare cases, mineralocorticoid hormones.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="bold">Central</content>
<content stylecode="bold">Nervous</content>
<content stylecode="bold"> System (CNS) Depressants</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Due to additive pharmacologic effect, the concomitant use of CNS depressants can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Consider dose reduction of one or both drugs. Monitor patients for respiratory depression, sedation, and hypotension <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#LINK_0c45ebd7-d085-42d2-af5e-4ee469ff9a4d">5.8</linkhtml>)]</content>.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Alcohol, benzodiazepines, and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="bold">Serotonergic</content>
<content stylecode="bold"> Drugs</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#LINK_ba87291a-6f0e-4668-9c5d-500e3957dab1">5.9</linkhtml>)]</content>.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Discontinue methadone hydrochloride tablets for oral suspension if serotonin syndrome is suspected.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT<sub>3</sub>receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "></td>
<td></td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="bold">Monoamine</content>
<content stylecode="bold">Oxidase</content>
<content stylecode="bold"> Inhibitors (MAOIs)</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#LINK_bee8702b-249a-4792-9281-7209713e734e">5.1</linkhtml>)]</content>.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>The use of methadone hydrochloride tablets for oral suspension is not recommended for patients taking MAOIs or within 14 days of stopping such treatment.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>phenelzine, tranylcypromine, linezolid</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="bold">Mixed Agonist/Antagonist</content>
<content stylecode="bold">and</content>
<content stylecode="bold">Partial</content>
<content stylecode="bold">Agonist</content>
<content stylecode="bold">Opioid Analgesics</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Patients maintained on methadone may experience withdrawal symptoms when given opioid antagonists, mixed agonist/antagonists, and partial agonists.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Avoid concomitant use.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>butorphanol, nalbuphine, pentazocine, buprenorphine</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="bold">Muscle</content>
<content stylecode="bold"> Relaxants</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Methadone may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Monitor patients for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of methadone hydrochloride tablets for oral suspension and/or the muscle relaxant as necessary.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="bold">Diuretics</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Monitor patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="bold">Anticholinergic</content>
<content stylecode="bold"> Drugs</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Monitor patients for signs of urinary retention or reduced gastric motility when methadone hydrochloride tablets for oral suspension is used concomitantly with anticholinergic drugs.</paragraph>
</td>
</tr>
</tbody>
</table>